Viemed Healthcare, Inc. - Common Shares (VMD)
Healthcare › Services-Misc Health & Allied Services, NEC
Price History
Feb 9, 2026 — Jul 7, 2026Investment Snapshot
- Trading 95% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 8.3% — below-average profitability
- Revenue growing at 21% annually
Viemed Healthcare, Inc. - Common Shares (VMD) is a Healthcare company operating in Services-Misc Health & Allied Services, NEC, listed on the NASDAQ , with a market capitalisation of $382 million . Key value metrics: P/E ratio 32.2, P/B ratio 2.66, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Viemed Healthcare, Inc. - Common Shares — Fundamental Analysis Summary
Viemed Healthcare, Inc. - Common Shares (VMD) is currently trading 95% above its Graham Number of $5.11, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 32.2x.
On financial health, VMD shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 8.3% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.06.
StockPik's composite Value Score for VMD is 70/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VMD reports a solid gross margin of 57.2% (sector average: 39.4%) and a modest operating margin of 7.0%.
VMD shows revenue growing at 21% year-over-year, with earnings growing at 33%.